中國醫療集團(08225.HK)前三季營業收入3331.6萬元 同比下降約40.3%
格隆匯11月14日丨中國醫療集團(08225.HK)公吿,截至2022年9月30日止9個月,集團錄得營業收入約人民幣3331.6萬元,較2021年同期營業收入下降約40.3%。集團錄得除税前利潤約人民幣1925.9萬元,較2021年同期除税前利潤下降約38.0%。每股盈利(基本)約為人民幣1.64仙,較2021年同期下降約36.5%。董事會建議不派發截至2022年九月30日止9個月股息。
在科研服務上,集團旗下“RWS萬全中心”是通過大資料真實臨牀研究重新篩選和組團現有藥品,尋找最佳治療的萬全策。集團成立生物樣品檢測實驗室,配置WatersUPLC-MS/MS.XevoTQS,正式對外開放,該實驗室主要服務臨牀研究特別是抗病毒藥物的臨牀研究實驗。
在商業模式上集團在疫情和數位醫療新時代,推出兩個模式,1.“研究型治療RWS-Therapy模式”,即通過真實世界臨牀研究開展對五大專寇裏能與疾病的臨牀和大資料研究,在研究中指導用藥治療,在治療中獲得醫療大資料再反過來指導研究。2“數位臨牀研究型推廣D-CRCO模式”(Digital數位元化、Clinical臨牀、Research研究、Commercialization商業化、Organization組織),用大資料臨牀研究精準賦能產品商業化。這兩個模式將數位元化重新定義研究型治療和研究型推廣替代傳統治療和商業化方式。
在大資料醫療服務上,公司與北京、上海、廣州等地的多家頂尖醫療機構,及高濟醫療、海王星辰、微醫集團和妙手醫療等百強連鎖和數字醫療集團建立研究數字型專區藥診,悦戒煙研究與治療專科、喜恩心理研究與治療專科、拜敏發熱咳嗽研究與治療專區、抗病毒藥研究與治療專區等,在疫情和後疫情時代都將發揮出對患者的巨大價值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.